Xeris Biopharma (XERS) news
Recent news
Xeris Biopharma outlook full-year 2026 total revenue guidance to $385 million to $390 million
AInvest Wire · Aug 6, 2026Xeris Biopharma sees FY revenue $385M to $390M, saw $380M to $390M
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has updated its financial outlook for the fiscal year, projecting total revenue in the range of $385 million to $390 million. This forecast aligns with the company’s previous guidance of $380 million to $390 million, indicating continued confidence in…
AInvest Wire · Aug 6, 2026Xeris Biopharma Q2 EPS USD -0.18
AInvest Wire · Aug 6, 2026Xeris Biopharma Holdings - Marla Persky to transition to lead independent director
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced a leadership transition within its board of directors, with Marla S. Persky assuming the role of independent chairperson effective August 1, 2024. This change follows the retirement of Paul R. Edick from his day-to-day operational and…
AInvest Wire · Jun 30, 2026Xeris Biopharma Holdings - appoints John Shannon as chair of the board
AInvest Wire · Jun 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.